Patented Drug Extension Strategies on Healthcare Spending: A Cost-Evaluation Analysis
نویسندگان
چکیده
BACKGROUND Drug manufacturers have developed "evergreening" strategies to compete with generic medication after patent termination. These include marketing of slightly modified follow-on drugs. We aimed to estimate the financial impact of these drugs on overall healthcare costs and also to examine the impact of listing these drugs in hospital restrictive drug formularies (RDFs) on the healthcare system as a whole ("spillover effect"). METHODS AND FINDINGS We used hospital and community pharmacy invoice office data in the Swiss canton of Geneva to calculate utilisation of eight follow-on drugs in defined daily doses between 2000 and 2008. "Extra costs" were calculated for three different scenarios assuming replacement with the corresponding generic equivalent for prescriptions of (1) all brand (i.e., initially patented) drugs, (2) all follow-on drugs, or (3) brand and follow-on drugs. To examine the financial spillover effect we calculated a monthly follow-on drug market share in defined daily doses for medications prescribed by hospital physicians but dispensed in community pharmacies, in comparison to drugs prescribed by non-hospital physicians in the community. Estimated "extra costs" over the study period were €15.9 (95% CI 15.5; 16.2) million for scenario 1, €14.4 (95% CI 14.1; 14.7) million for scenario 2, and €30.3 (95% CI 29.8; 30.8) million for scenario 3. The impact of strictly switching all patients using proton-pump inhibitors to esomeprazole at admission resulted in a spillover "extra cost" of €330,300 (95% CI 276,100; 383,800), whereas strictly switching to generic cetirizine resulted in savings of €7,700 (95% CI 4,100; 11,100). Overall we estimated that the RDF resulted in "extra costs" of €503,600 (95% CI 444,500; 563,100). CONCLUSIONS Evergreening strategies have been successful in maintaining market share in Geneva, offsetting competition by generics and cost containment policies. Hospitals may be contributing to increased overall healthcare costs by listing follow-on drugs in their RDF. Therefore, healthcare providers and policy makers should be aware of the impact of evergreening strategies.
منابع مشابه
The effect of pharmaceutical patent term length on research and development and drug expenditures in Canada.
While pharmaceutical patent terms have increased in Canada, increases in patented drug spending have been mitigated by price controls and retrenchment of public prescription drug subsidy programs. We estimate the net effects of these offsetting policies on domestic pharmaceutical R&D expenditures and also provide an upper-bound estimate on the effects of these policies on Canadian pharmaceutica...
متن کاملHealthcare reform in the United States and China: pharmaceutical market implications
OBJECTIVES The United States and China are broadening health insurance coverage and increasing spending on pharmaceuticals, in contrast to other major economies that are reducing health spending and implementing a variety of drug price controls. This article analyzes the implications of health system reforms in the United States and China for national pharmaceutical markets. It follows a histor...
متن کاملThe Misguided War Against Medicines 2008
Executive summary / 1 Introduction / 7 The particular impact of new or " patented " drugs on government health care costs / 8 The impact of all types of drugs on government health care costs / 18 The real cause of unsustainable growth in government health spending / 25 Research suggests that government health spending in Canada is growing at an unsus-tainable pace [Skinner and Rovere, 2006; 200...
متن کاملA Review of Approaches for the Management of Specialty Pharmaceuticals in the United States
With increased innovation and development of specialty pharmaceuticals, the US and global healthcare industries are looking to implement appropriate management strategies to control both utilization and costs. Specialty pharmaceuticals are high-cost medications that treat complex, chronic, rare, and difficult-to-manage conditions. These drugs require special drug handling, appropriate clinical ...
متن کاملHealthcare cost drivers: where does the money go?
• Healthcare spending continues to grow in Canada; it is expected to surpass the $200 billion milestone for the first time in 2011. However, the speed of growth is the slowest in the last 15 years. • Canada is forecast to spend about $7 billion more on healthcare in 2011 than in 2010— or about $150 more per citizen (about $5800 per capita). This represents an estimated annual growth rate of 4%,...
متن کامل